Faculty Collaboration Database

Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. J Thorac Oncol 2014 May;9(5):702-9

Date

03/26/2014

Pubmed ID

24662458

Pubmed Central ID

PMC4982660

DOI

10.1097/JTO.0000000000000146

Scopus ID

2-s2.0-84899488878 (requires institutional sign-in at Scopus site)   40 Citations

Abstract

BACKGROUND: While platinum-based doublet chemotherapy is standard of care for patients presenting with metastatic non-small-cell lung cancer, the optimal platinum agent (cisplatin versus carboplatin) is unclear. We therefore compared survival and toxicity among persons receiving these agents at Department of Veterans Affairs hospitals.

METHODS: We used the Veterans Affairs Central Cancer Registry to identify veterans presented between 2001 and 2008 with metastatic non-small-cell lung cancer, then selected those receiving initial platinum doublet chemotherapy. We compared survival between those receiving cisplatin and carboplatin using multivariable Cox proportional hazards models and propensity score analyses to adjust for imbalances in demographics and clinical characteristics.

RESULTS: We identified 4352 eligible persons; 4061 (93%) received carboplatin. Patients treated with cisplatin were younger (median age 61 versus 63, p < 0.01) and had less comorbidities (summary comorbidity score > 2, 7.7% versus 12.8%, p = 0.01) and higher eGFR (87 versus 84 mL/min/1.73 m). Median survival was similar for persons receiving cisplatin and carboplatin (8.1 versus 7.5 months, p = 0.54). In an adjusted survival analyses, the use of cisplatin was not associated with a better survival (hazard ratio 0.98, 95% confidence interval 0.84-1.14, p = 0.79). We performed subgroup analysis defined by histology and second agent, the hazard ratio for mortality ranged spanned 1 and none of these approached statistical significance (all p values > 0.20). Cisplatin-treated patients were more likely to have more hospitalization (1.7 versus 1.3, p < 0.01) and outpatient visits (11 versus 9.6, p < 0.01). Cisplatin-treated patient had more subsequent encounters for infection (41.6% versus 34.3%, p < 0.01) and acute kidney injury/dehydration (29.2% versus 15.5%, p < 0.01) CONCLUSIONS:: Patients receiving cisplatin and carboplatin-based doublets did not have significantly different survival, but cisplatin use was associated with an increase morbidity and healthcare use.

Author List

Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J

Authors

Aniko Szabo PhD Professor in the Institute for Health and Equity department at Medical College of Wisconsin
Jeffrey Whittle MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Ambulatory Care
Antineoplastic Combined Chemotherapy Protocols
Camptothecin
Carboplatin
Carcinoma, Non-Small-Cell Lung
Cisplatin
Deoxycytidine
Etoposide
Female
Glutamates
Guanine
Hospitalization
Humans
Lung Neoplasms
Male
Middle Aged
Paclitaxel
Pemetrexed
Registries
Retrospective Studies
Survival Rate
Taxoids
United States
United States Department of Veterans Affairs
Vinblastine